Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26092953 | 1.00 | USP2 (0.39) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL7383379 | 0.88 | LMNA (0.39) | USP2LMNAL3MBTL1TDP1OR51E2 | |
| SCHEMBL15754347 | 0.84 | LMNA (0.48) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL7510580 | 0.84 | LMNA (0.55) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL599666 | 0.84 | LMNA (0.48) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL26091297 | 0.84 | LMNA (0.48) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL3851276 | 0.84 | LMNA (0.48) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| Hydrochloric Acid SCHEMBL28610464 | 0.82 | LMNA (0.46) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL20315375 | 0.80 | USP2 (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL20518531 | 0.80 | USP2 (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376087-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | Santaris Pharma A/S (DK) | 2011-10-19 | — | — | EP | claimed |
| CN-102223886-A | Erbb-3 (her3)-selective combination therapy | ENZON PHARMACEUTICALS INC | 2011-10-19 | — | — | CN | claimed |
| WO-2010054051-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | SANTARIS PHARMA A/S (DK) | 2010-05-14 | — | — | WO | claimed |
| US-5045338-A | Ester imides, acylated aminoalcohol derivatives | NABISCO BRANDS, INC. (US) | 1991-09-03 | — | — | US | claimed |
| EP-4658408-A2 | RESPIRATORY BIOMARKER PANEL | Cepheid (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4526479-A1 | MVP CARTRIDGE AND METHODS OF USE AND MANUFACTURE | Cepheid (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024163366-A9 | RESPIRATORY BIOMARKER PANEL | CEPHEID (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024163366-A2 | RESPIRATORY BIOMARKER PANEL | CEPHEID (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-117106887-A | Compositions and methods for diagnosing and treating tuberculosis | 塞弗德公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023225362-A1 | MVP CARTRIDGE AND METHODS OF USE AND MANUFACTURE | CEPHEID (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-116635538-A | Compositions and methods for diagnosing and treating tuberculosis | 塞弗德公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116348767-A | Method for diagnosing tuberculosis and distinguishing active tuberculosis from latent tuberculosis | 西菲伊德公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023070123-A1 | COMPOSITIONS AND METHODS OF DIAGNOSING AND TREATING TUBERCULOSIS | CEPHEID (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-105209634-B | Enzyme arrest method | 牛津纳米孔技术公司 | 2020-05-12 | — | — | CN | disclosed |
| US-7393954-B2 | Process for the production of pentostatin aglycone and pentostatin | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-20040181052-A1 | Process for the production of pentostatin aglycone and pentostatin | APPLIED SILICONE COMPANY LLC | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181052-A1 | Process for the production of pentostatin aglycone and pentostatin | DTYMK, RNGTT, DDOST | USP2 3600/4885SLCO1B1 4318/4885LMNA 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.